Members of Osteoporosis Canada’s Scientific Advisory Council would like announce this year’s Lindy Fraser Award winner as chosen by the members of the SAC. Osteoporosis Canada established this award in 1993 […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]

Support groups, one of the online programs offered by Osteoporosis Canada, are all about connection. They connect people who not only live with osteoporosis but want to live well with […]

Osteoporosis Canada helps educate Canadians on the importance of bone health and improve the quality of life for those diagnosed with osteoporosis. Many supporters of Osteoporosis Canada find peace of […]